Search

Displaying results 9671 - 9680 of 10000 in total
  1. Drug

    Sibofimloc

    go.drugbank.com/drugs/DB16400
    Investigational

    Sibofimloc is under investigation in clinical trial NCT03943446 (TAK-018 for Prevention of the Recurrence of Postoperative Crohn's Disease (CD)).

  2. Drug

    Etavopivat

    go.drugbank.com/drugs/DB18176
    Investigational

    Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for the treatment of sickle cell disease.

  3. Drug

    UV1

    go.drugbank.com/drugs/DB18470
    Experimental

    UV1 is a cancer vaccine consisting of p719-20, p728, and p725 synthetic peptides representing fragments of the hTERT subunit

  4. Drug

    PF-06273340

    go.drugbank.com/drugs/DB12269
    Investigational

    Pf 06273340 is under investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects … of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)).

  5. Drug

    Lutetium (177Lu) NeoB

    go.drugbank.com/drugs/DB30389
    Investigational

    Lutetium (177Lu) NeoB is a biologic drug. … Lutetium (177Lu) NeoB is under investigation in clinical trial NCT06379217 (NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine

    Synonyms: Lu-NeoB, [177Lu]Lu-NeoB
  6. Drug

    Froniglutide

    go.drugbank.com/drugs/DB16178
    Investigational

    Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM). … Glymera is under investigation in clinical trial NCT01658501 (Phase 2b Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group Study to Assess the PD Response and Safety of

  7. Drug

    JPC-3210

    go.drugbank.com/drugs/DB15609
    Experimental

    JPC-3210 is a potent antimalarial agent. … , and favourable preclinical pharmacokinetics including a lengthy plasma elimination half-life.

  8. Drug

    (S)-5-(7-(4-(4-Ethyl-4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methylisoxazole

    go.drugbank.com/drugs/DB08725
    Experimental

    These are aromatic compounds containing an ether group substituted with a benzene ring. This substance targets the protein genome polyprotein. … (S)-5-(7-(4-(4-Ethyl-4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methylisoxazole is a solid. This compound belongs to the phenol ethers.

  9. Drug

    MUL001

    go.drugbank.com/drugs/DB18534
    Experimental

    MUL001 is live attenuated strain of _Salmonella typhimurium_ being investigated for the treatment of schwannomas.

  10. Drug

    V590

    go.drugbank.com/drugs/DB16437
    Experimental

    Other features of this vaccine include potential activity with oral administration _via_ a swish-and-swallow protocol[L30583]. … By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose[L30583].